Patient Support Services Contact Us

About Coherus

Scientific Advisory Board

Scientists at leading research institutions and independent consultants make up our scientific advisory board, providing external perspective and a forum for discussions about product development, manufacturing processes, market trends, and more.

  • Alan Herman, Ph.D.

    Chairman Emeritus, former Chief Scientific Officer at Coherus BioSciences

    • Alan Herman, Ph.D.

      Chairman Emeritus, former Chief Scientific Officer at Coherus BioSciences

      FORMERLY

      Genentech, Amgen, Merck, Coherus

      Dr. Herman has more than 32 years of experience at some of the most significant companies in the biopharmaceutical space. He started his career at Merck, working on recombinant hepatitis B vaccine. Later, at Genentech, he focused on process development and pharmaceutics, contributing to the development of human growth hormone, tissue plasminogen activator, and interferon. At Amgen, he started the Analytical Research and Development Department, which he managed for 11 years. The cutting-edge analytics that emerged from this effort significantly contributed to radical changes in the regulatory review of recombinant products, leading to the “well defined biological products” characterization that enabled more rapid product development. This work helped lay the groundwork for biosimilar products in regulated markets.
      During Dr. Herman’s tenure at Amgen, his department contributed to more than 20 INDs and several BLAs. In 2003, he became Senior Director of Quality Control for Tercica, Inc., a start-up that in-licensed a late-stage compound (IGF-1) from Genentech. His group designed a comparability program that would minimize the need for further clinical trials. Dr. Herman also supervised contract laboratories in areas such as product characterization, method development and validation, release testing, and clinical and commercial stability. Dr. Herman served as CSO and Vice President of Product Development at Althea until 2011, when he joined Coherus Biosciences.
      Dr. Herman holds B.S. and M.S. degrees in biology from Indiana University of Pennsylvania and a Ph.D. in protein chemistry from Duke University.

  • Barbara K. Finck, M.D.

    Chief Clinical Advisor, former Chief Medical Officer at Coherus BioSciences

    • Barbara K. Finck, M.D.

      Chief Clinical Advisor, former Chief Medical Officer at Coherus BioSciences

      FORMERLY

      Immunex, PDL Biopharma, Osprey Pharmaceuticals, NKT Therapeutics

      Dr. Finck is a board certified rheumatologist with more than 25 years of preclinical and clinical drug development experience in academic and biopharmaceutical settings. During her rheumatology training at University of California, San Francisco she studied the effects of CTLA4-Ig (subsequently developed and marketed as Orencia®) in a murine lupus nephritis model.

      Dr. Finck, whose drug development activities have spanned multiple therapeutic areas, started her pharmaceutical career at ALZA as medical director for early clinical development of Ditropan-XL®, to treat spasms of the bladder. She subsequently held senior level positions at a half-dozen innovative biopharmaceutical companies. At Immunex (later acquired by Amgen) she was lead medical director for the Phase III clinical development of Enbrel® in rheumatoid arthritis and juvenile idiopathic arthritis. At Eos Biotechology, she was VP for Clinical Development. In addition, she was on the executive teams at PDL Biopharma (VP, Clinical Development), Osprey Pharmaceuticals USA, Inc. (Senior VP, Research and Development, and Chief Medical Officer), and NKT Therapeutics, Inc. (Chief Medical Officer).

      Throughout her career in pharmaceutical development, Dr. Finck has demonstrated the ability to build effective teams and alliances, as well as a personal passion for developing therapeutics to treat diseases where there is significant unmet medical need.

      Dr. Finck earned her B.S. from UC Santa Barbara, and her M.D. from UCSF, where she also completed her Internship and Residency in Internal Medicine, and her Fellowship in Rheumatology.

  • V. Bryan Lawlis, Ph.D.

    Former President and Chief Executive Officer of Itero Biopharmaceuticals

    • V. Bryan Lawlis, Ph.D.

      Former President and Chief Executive Officer of Itero Biopharmaceuticals

      FORMERLY

      Genentech

      V. Bryan Lawlis, Ph.D. has served on our Board of Directors since May 2014 and prior to that he served as the chairman of our Scientic Advisory Board from November 2012, until he joined the board in May 2014.

      Since August 2011, he has served as the President and Chief Executive Officer of ltero Biopharmaceuticals, LLC, a privately held limited liability holding company, which has held the assets of ltero Biopharmaceuticals, Inc., or Itero Biopharmaceuticals, since August 2011. Dr. Lawlis co-founded and served as President and Chief Executive Officer of Itero Biopharmaceuticals, from 2006, until it discontinued operations in August 2011. Prior to that, he served as President and Chief Executive Officer of Aradigm Corporation, a pharmaceutical company, from August 2004, and served on its board of directors from February 2005, continuing in both capacities until August 2006. Dr. Lawlis served as Aradigm Corporation’s President from June 2003 to August 2004, and as its Chief Operating Officer from November 2001 to June 2003. Previously, Dr. Lawlis co-founded Covance Biotechnology Services, Inc., a contract biopharmaceutical manufacturing company, served as its President and Chief Executive Officer from 1996 to 1999, and as Chairman from 1999 to 2001, when it was sold to Diosyth RTP, Inc., a division of Akzo Nobel, NV. From 1981 to 1996, Dr. Lawlis was employed at Genencor, Inc., a biotechnology company, and Genentech. His last position at Genentech was Vice President of Process Sciences. Dr. Lawlis has served on the boards of directors of two privately held companies, Sutro Biopharmaceuticals, Inc. since 2003 and Reform Biologics, LL since February 2014. He has also served on the boards of directors at BioMarin Pharmaceutical Inc., a public biopharmaceutical company since June 2007, and Geron Corporation, a public biopharmaceutical company, since March 2012.

      Dr. Lawlis holds a B.A. in Microbiology from the University of Texas at Austin, and a Ph.D. in Biochemistry from Washington State University.

      We believe Dr. Lawlis is qualified to serve on our Board of Directors due to his longtime involvement in the biotechnology industry, and extensive service as a director or officer of other life sciences companies.

  • William F. Bennett, Ph.D.

    Principal, Bioscope Associates

    • William F. Bennett, Ph.D.

      Principal, Bioscope Associates

      FORMERLY

      Genentech

      William F. Bennett, Ph.D. is a Principal of Bioscope Associates LLC.

      Until 2009, he was Sr. Director of Regulatory Policy at Genentech and led the Genentech Biosimilars working group. He was at Genentech for 18 years altogether, having held high-level positions in Research, Bioprocess Development and Regulatory Affairs. He helped guide Genentech over many years through his participation on the Research Review, Product Development, Process Development Review and Appointments and Promotions Committees. During a period away from Genentech, as CSO at Sensus Corporation, he led the research and development of Somavert (a treatment for acromegaly) and was the Vice President of Research at Cor Therapeutics as well as Senior Vice President of R&D at Hyseq/Nuvelo. Dr. Bennett returned to Genentech in 2003.

      Dr. Bennett has a B.A. in Chemistry from TCU and a Ph.D. in Biochemistry from the University of Texas Southwestern Medical School. He was named a Distinguished Alumnus of TCU in 2010 and serves on the TCU Science & Engineering Advisory Board.

  • Andrew J.S. Jones, D. Phil.

    Independent Consultant

    • Andrew J.S. Jones, D. Phil.

      Independent Consultant

      FORMERLY

      Genentech

      Andrew J.S. Jones, D. Phil, spent 23 years from 1981 to 2004, at Genentech. Initially a scientist in the Protein Biochemistry Department, he was the founding Director of the Medical and Analytical Chemistry Department from 1983 to 1987. As staff scientist from 1988, he played various roles in the company including project team leader and also worked in the Pharmaceutical R&D Department from 1987 to 1994. Since 2004, Dr. Jones has worked as a consultant to various biopharmaceutical companies. He was the Head of the Scientific Advisory Board for Itero Biopharmaceuticals from 2009 to 2011.

      Dr. Jones obtained his B.A. (Honors) degree in Biochemistry from St. John’s College, Oxford University. He received his D. Phil. degree in Biology from the University of York and performed postdoctoral research at McMaster University, under a Multiple Sclerosis Society of Canada Fellowship, and also at Cornell University.

  • James Miller, Ph.D.

    Independent Consultant

    • James Miller, Ph.D.

      Independent Consultant

      FORMERLY

      Amgen, Regeneron

      James A. Miller, Ph.D. is currently an independent consultant to the biopharmaceutical industry.

      Dr. Miller was recently Vice President of Process Development at Insmed, Inc., where he was involved with the sale of the company to Merck, Inc., with whom he continued to work as Senior Director of Process Development at the newly formed entity, Merck Boulder. From 2000 to 2003, Dr. Miller was Executive Vice President and co-founder of Saronyx, Inc., a company that developed web-enabled interfaces for data exchange between pharmaceutical development specialists and contract research organizations. From 1998 to 2000, he was Senior Director of Preclinical Development at Regeneron Pharmaceuticals, Inc., where he was responsible for the departments of pharmacology, pharmacokinetics, analytical assay and drug formulation/stability. From 1987 to 1998, Dr. Miller worked at Amgen in a number of roles, including founding the neurobiology department and undertaking leadership of the BDNF development team.

      Dr. Miller received his B.S. degree in Biology from the University of Oregon and a Ph.D. in Chemistry from the California Institute of Technology. He also received postdoctoral training in Physiology at the University of Colorado Medical School and the Yale University School of Medicine.

  • Carl Ware, Ph.D.

    Director, Sanford-Burnham Medical Research Institute

    • Carl Ware, Ph.D.

      Director, Sanford-Burnham Medical Research Institute

      FORMERLY

      Carl F. Ware, Ph.D. is a Director and Professor at the Infectious and Inflammatory Disease Center at the Sanford Burnham Prebys Medical Discovery Institute in La Jolla California. He is a leading immunologist and virologist, internationally recognized for his scientific discoveries and advances in the study of the immune system, leading to new therapeutics for autoimmune and viral diseases and cancer.

      Dr. Ware received his doctorate in 1979 in Molecular Biology and Biochemistry at the University of California, Irvine, where he began his scientific research career by studying tumor destroying cytokines with Professor Gale A. Granger. Dr. Ware’s postdoctoral training included research with Dr. Jack Strominger and Dr. Tim Springer at the Dana-Farber Cancer Institute, Harvard Medical School. Dr. Ware established his own research laboratory in 1982 in the Biomedical Sciences Program at the University of California, Riverside, advancing to full professor in 1993. In 1996, he joined the La Jolla Institute for Allergy and Immunology as head of the Division of Molecular Immunology.

      In 2010, he was recruited to the Sanford Burnham Prebys Medical Discovery Institute as Center Director, and also holds a joint appointment in the Department of Biology at the University of California, San Diego.